GH vs CAI vs DGX Stock Comparison

Guardant Health, Caris Life Sciences and Quest Diagnostics Prices as of Nov 13, 2026 Peers: Industry group
GH Guardant Health, Inc.
$151.70 -6.9% 1M +61.2% 1Y
Market cap
$19.66B
P/E
–
Revenue (TTM)
$1.28B
Div. yield
–
Diagnostic Labs Healthcare
1 win
DGX Quest Diagnostics Inc
$259.78 +11.3% 1M +38.5% 1Y
Market cap
$28.74B
P/E
25.5x
Revenue (TTM)
$11.84B
Div. yield
0.01%
Diagnostic Labs Healthcare
6 wins

Head to Head

11 decided of 12

Quest Diagnostics leads on 6 of the 12 questions below (Quest Diagnostics 6, Caris Life Sciences 4, Guardant Health 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionGHCAIDGXLeader
Larger companyMarket capitalisation $19.66B $6.17B $28.74B DGX
Cheaper on earningsLower P/E, profitable companies only -40.5x 64.3x 25.5x DGX
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 230.4x 23.7x DGX
Faster revenue growthRevenue growth, trailing twelve months +41.7% +61.5% +9.1% CAI
More profitableNet margin, trailing twelve months -37.9% 9.2% 9.5% DGX
Better return on capitalReturn on invested capital — 13.7% 9.9% CAI
Less leveragedLower net debt / EBITDA — -2.3x 2.1x CAI
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.01% –
Better 1-year returnPrice return, last 12 months +61.2% -5.2% +38.5% GH
Better 5-year returnAnnualised price return, 5 years +7.9%/yr — +11.6%/yr DGX
Less volatileAnnualised volatility, 1 year 53.0% 71.8% 23.8% DGX
Higher overall scoreMean of the five percentile scores vs peers 27/100 66/100 63/100 CAI

Percentile Scorecard

GHCAIDGX

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisGHCAIDGX
Valuation 15 #84 of 99 25 #75 of 99 61 #39 of 99
Growth 44 #50 of 89 99 #2 of 89 41 #53 of 89
Profitability 9 #84 of 92 70 #28 of 92 82 #17 of 92
Financial Health 54 #48 of 103 81 #20 of 103 61 #41 of 103
Shareholder Returns 13 #55 of 63 55 #29 of 63 68 #21 of 63
Overall 27 66 63
  • GH ranked among 103 companies in Healthcare Providers
  • CAI ranked among 103 companies in Healthcare Providers
  • DGX ranked among 103 companies in Healthcare Providers

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodGHCAIDGXSPY
1 month -6.9%-23.8%+11.3% -2.0%
3 months -3.5%+5.7%+10.9% -2.8%
6 months +59.8%+58.4%+39.2% +2.0%
Year to date +48.5%-14.6%+49.7% +10.6%
1 year +61.2%-5.2%+38.5% +12.2%
3 years +519.4%—+94.2% +68.1%
3 years, per year +83.7%—+24.8% +18.9%
5 years +46.1%—+73.2% +61.4%
5 years, per year +7.9%—+11.6% +10.1%
10 years ——+218.9% +248.5%
10 years, per year ——+12.3% +13.3%

Risk

MeasureGHCAIDGXSPY
Volatility, 1Y 53.0%71.8%23.8% 13.6%
Downside volatility, 1Y 50.7%74.4%18.5% 13.9%
Beta vs S&P 500, 1Y 1.321.92-0.04 1.00
Return / volatility, 1Y 1.15-0.071.62 0.90
Max drawdown, 5Y -85.0%-63.0%-30.3% -25.4%
From 52-week high -19.0%-36.2%0.0% -3.2%
52-week high $187.22$36.14$259.78 $779.14
52-week low $78.60$14.55$173.49 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleGHCAIDGX
P/E now vs peer median -42.0xmedian 22.4x 68.1xmedian 22.4x 25.3xmedian 22.4x
P/S now vs peer median 16.0xmedian 1.3x 6.3xmedian 1.3x 2.4xmedian 1.3x
EV/EBITDA now vs peer median -40.6xmedian 14.2x 37.5xmedian 14.2x 14.4xmedian 14.2x
P/FCF now vs peer median -88.0xmedian 19.0x 228.5xmedian 19.0x 20.8xmedian 19.0x
P/B now vs peer median -74.1xmedian 2.6x 10.3xmedian 2.6x 3.6xmedian 2.6x
PEG now vs peer median -72.47median 0.84 —median 0.84 1.73median 0.84

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsGHCAIDGX
Revenue $1.28B $1.05B $11.84B
Gross profit $833.70M $724.14M $3.92B
Operating income -$504.04M $139.94M $1.72B
Net income -$485.07M $96.06M $1.18B
Free cash flow -$232.15M $28.91M $1.38B
R&D $386.67M $129.36M –
EPS (diluted) $-3.61 $0.33 $10.08
Cash & equivalents $1.03B $665.32M $797.00M
Total debt – $393.27M $5.55B
Shares (diluted) 134.42M 295.14M 112.00M
Enterprise value $15.27B $2.99B $26.51B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricGHCAIDGX
P/E -42.0x 68.1x 25.3x
P/FCF -88.0x 228.5x 20.8x
P/Operating cash flow -117.8x 78.7x 14.6x
P/S 16.0x 6.3x 2.4x
P/B -74.1x 10.3x 3.6x
P/Tangible book -67.9x 10.3x 4.5x
EV/EBITDA -40.6x 37.5x 14.4x
EV/EBIT -38.5x 44.5x 19.3x
EV/Revenue 15.2x 5.9x 2.8x
EV/FCF -83.6x 215.6x 24.2x
EV/Operating cash flow -111.9x 74.3x 17.1x
PEG (3Y EPS CAGR) -72.47 – 1.73

Growth

14 metrics
MetricGHCAIDGX
Revenue growth (1Y) 41.7% 61.5% 9.1%
Revenue CAGR (3Y) 33.6% – 8.4%
Gross profit growth (1Y) 44.9% 86.2% 8.5%
Gross profit CAGR (3Y) – – 8.4%
Operating income growth (1Y) -13.9% 274.2% 12.5%
Operating income CAGR (3Y) 0.6% – 15.1%
Net income growth (1Y) -21.6% 151.4% 15.0%
Net income CAGR (3Y) -3.9% – 12.9%
EPS growth (1Y) -12.9% 114.2% 17.6%
EPS CAGR (3Y) 0.6% – 14.6%
Operating cash flow growth (1Y) 22.2% 15,464% 3.5%
Operating cash flow CAGR (3Y) 19.9% – 21.8%
Free cash flow growth (1Y) 11.5% 306.4% -1.3%
Free cash flow CAGR (3Y) 13.9% – 32.1%

Profitability

14 metrics
MetricGHCAIDGX
Gross margin 65.2% 69.1% 33.1%
EBITDA margin -37.4% 15.9% 19.5%
Operating margin -39.4% 13.4% 14.6%
Pretax margin -38.0% 9.3% 12.6%
Net margin -37.9% 9.2% 9.5%
FCF margin -18.2% 2.8% 11.6%
Operating cash flow margin -13.6% 8.0% 16.5%
Return on equity – 15.5% 15.0%
Return on assets -25.5% 7.7% 6.9%
Return on invested capital – 13.7% 9.9%
Return on capital employed -33.0% 12.9% 11.3%
Asset turnover 0.7x 0.8x 0.7x
Cash conversion (OCF / net income) 0.4x 0.9x 1.7x
Stock comp / revenue 16.5% 6.7% 0.7%

Financial Health

11 metrics
MetricGHCAIDGX
Debt / assets – 31.3% 32.2%
Debt / equity – 0.6x 0.7x
Net debt / EBITDA – -2.3x 2.1x
Debt / FCF – 13.6x 4.0x
Liabilities / assets 114.6% 49.1% 53.8%
Equity / assets -14.6% 50.9% 46.2%
Interest coverage -96.6x 3.3x 6.5x
Current ratio 3.6x 6.7x 1.7x
Quick ratio 3.3x 5.7x 1.4x
Cash ratio 2.8x 4.8x 0.4x
Altman Z-score 3.60 5.68 3.82

Shareholder Returns

7 metrics
MetricGHCAIDGX
Dividend yield – – 1.3%
Net buyback yield -2.0% 0.0% 1.1%
Shareholder yield -2.0% 0.0% 2.4%
Payout ratio (earnings) – – 31.3%
Payout ratio (FCF) – – 26.8%
Dividend growth (1Y) – – 6.3%
Dividend CAGR (3Y) – – 6.1%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusGHCAIDGX
Forward P/E – 230.4xFY2026 23.7xFY2026
EPS, next fiscal year $-3.46FY2026 $0.10FY2026 $10.98FY2026
EPS growth, next FY – – +11.5%FY2026
EPS growth, the year after – +190.0% +6.6%
Revenue, next fiscal year $1.43BFY2026 $1.07BFY2026 $11.25BFY2026
Revenue growth, next FY +45.5%FY2026 +31.4%FY2026 +1.9%FY2026
Revenue growth, the year after +26.0% +22.4% +7.7%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersGHCAIDGX
Held by institutions 100.0% 52.0% 94.4%
Institutions holding 597 246 1,098
Change in shares held, QoQ -2.5% -6.3% +2.7%
Institutions buying 356 174 549
Institutions selling 180 47 342
Buyers to sellers 1.98 3.70 1.61

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

GHCAIDGX
GH 1.00 0.49 0.22
CAI 0.49 1.00 0.22
DGX 0.22 0.22 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, GH, CAI and DGX?

Quest Diagnostics (DGX) is the largest by market capitalisation: Guardant Health (GH) $19.66B, Caris Life Sciences (CAI) $6.17B, Quest Diagnostics (DGX) $28.74B.

Which stock is cheaper, GH, CAI and DGX?

Quest Diagnostics (DGX) trades on the lowest price-to-earnings ratio (Guardant Health (GH) -40.5x, Caris Life Sciences (CAI) 64.3x, Quest Diagnostics (DGX) 25.5x). On next year's consensus earnings, Quest Diagnostics (DGX) is cheapest (Caris Life Sciences (CAI) 230.4x, Quest Diagnostics (DGX) 23.7x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Caris Life Sciences (CAI) grew revenue fastest over the trailing twelve months: Guardant Health (GH) +41.7%, Caris Life Sciences (CAI) +61.5%, Quest Diagnostics (DGX) +9.1%.

Which company is more profitable?

Quest Diagnostics (DGX) has the highest net margin (Guardant Health (GH) -37.9%, Caris Life Sciences (CAI) 9.2%, Quest Diagnostics (DGX) 9.5%). On return on invested capital, Caris Life Sciences (CAI) leads (Caris Life Sciences (CAI) 13.7%, Quest Diagnostics (DGX) 9.9%).

Which stock has performed better?

Over the past year Guardant Health (GH) returned the most: Guardant Health (GH) +61.2%, Caris Life Sciences (CAI) -5.2%, Quest Diagnostics (DGX) +38.5%. Over five years, Quest Diagnostics (DGX) compounded fastest (Guardant Health (GH) +7.9%/yr, Quest Diagnostics (DGX) +11.6%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Guardant Health (GH) 0.00%, Caris Life Sciences (CAI) 0.00%, Quest Diagnostics (DGX) 0.01%. Guardant Health (GH) and Caris Life Sciences (CAI) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Quest Diagnostics (DGX) has been the steadiest (Guardant Health (GH) 53.0%, Caris Life Sciences (CAI) 71.8%, Quest Diagnostics (DGX) 23.8%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, GH, CAI and DGX?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Quest Diagnostics (DGX) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.